A fully accurate explaination here Sir:

#C4CT Wrap-up and the Decision to Present Interim LP-002 Data Posted on Monday, August 4th, 2014 at 4:01 pm

http://www.thechairmansblog.com/amarantus-bio...pWIF7.dpuf

Quote:

---

"....Dr. Louis Kirby shared some positive top-line interim data from the Company’s ongoing LP-002 clinical study for LymPro where we demonstrated that with a single marker, CD19, we were able to distinguish Alzheimer’s disease from healthy controls in a population of 44 subjects. The Company had been planning on sharing top-line data from the full 72 subject study, and was disappointed this was not possible at #C4CT. When the Company became aware that 3 of the 4 sites had not completed their full enrollment, in part due to stringency in the Alzheimer’s subject selection criteria, we also became aware that one of the sites had exceeded its enrollment criteria as it was able to get through Institutional Review Board (IRB) approval well ahead of the other sites. We decided to un-blind the single site and perform an interim analysis for the purpose of being able to keep our previously outlined timeline on LymPro commercialization, and because #C4CT was a unique opportunity to recruit collaborators for the LymPro project. We will continue to focus our efforts on extracting the best univariate markers from LymPro through the completion of the LP-002 bridging study ahead of endeavoring to establish the multivariate predictive modeling that will become the basis of the ultimate clinical diagnostic that will be used commercially."

---